These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 11113355)

  • 1. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons.
    German DC; Liang CL; Manaye KF; Lane K; Sonsalla PK
    Neuroscience; 2000; 101(4):1063-9. PubMed ID: 11113355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter.
    Speciale SG; Liang CL; Sonsalla PK; Edwards RH; German DC
    Neuroscience; 1998 Jun; 84(4):1177-85. PubMed ID: 9578404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata.
    Staal RG; Sonsalla PK
    J Pharmacol Exp Ther; 2000 May; 293(2):336-42. PubMed ID: 10773000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.
    Masilamoni GJ; Bogenpohl JW; Alagille D; Delevich K; Tamagnan G; Votaw JR; Wichmann T; Smith Y
    Brain; 2011 Jul; 134(Pt 7):2057-73. PubMed ID: 21705423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.
    Taylor TN; Alter SP; Wang M; Goldstein DS; Miller GW
    Neuropharmacology; 2014 Jan; 76 Pt A(0 0):97-105. PubMed ID: 24025942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroPET imaging of vesicular monoamine transporter 2 revealed the potentiation of (+)-dihydrotetrabenazine on MPTP-induced degeneration of dopaminergic neurons.
    Xu Y; Tang J; Liu C; Zhao C; Cao S; Yu H; Chen Z; Xie M
    Nucl Med Biol; 2021; 96-97():9-18. PubMed ID: 33647803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of membrane and vesicular monoamine transporters in the neurotoxic and hypothermic effects of 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH(2)-MPTP).
    Numis AL; Unger EL; Sheridan DL; Chisnell AC; Andrews AM
    Mol Pharmacol; 2004 Sep; 66(3):718-27. PubMed ID: 15322265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Staal RG; Yang JM; Hait WN; Sonsalla PK
    Brain Res; 2001 Aug; 910(1-2):116-25. PubMed ID: 11489261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
    Staal RG; Hogan KA; Liang CL; German DC; Sonsalla PK
    J Pharmacol Exp Ther; 2000 May; 293(2):329-35. PubMed ID: 10772999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.
    Liang CL; Nelson O; Yazdani U; Pasbakhsh P; German DC
    J Comp Neurol; 2004 May; 473(1):97-106. PubMed ID: 15067721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice.
    Ekue A; Boulanger JF; Morissette M; Di Paolo T
    J Neuroendocrinol; 2002 Sep; 14(9):731-6. PubMed ID: 12213134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
    Mavridis M; Degryse AD; Lategan AJ; Marien MR; Colpaert FC
    Neuroscience; 1991; 41(2-3):507-23. PubMed ID: 1870701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area.
    Adelbrecht C; Agid Y; Raisman-Vozari R
    Brain Res Mol Brain Res; 1996 Dec; 43(1-2):291-300. PubMed ID: 9037545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons.
    Cleren C; Naudin B; Costentin J
    Brain Res; 2003 Nov; 989(2):187-95. PubMed ID: 14556940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP?
    Herrero MT; Hirsch EC; Kastner A; Ruberg M; Luquin MR; Laguna J; Javoy-Agid F; Obeso JA; Agid Y
    Neuroscience; 1993 Sep; 56(2):499-511. PubMed ID: 8247275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains.
    Kilbourn M; Frey K
    Eur J Pharmacol; 1996 Jun; 307(2):227-32. PubMed ID: 8832225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
    Srinivasan J; Schmidt WJ
    Eur J Neurosci; 2003 Jun; 17(12):2586-92. PubMed ID: 12823465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity.
    Thomas B; von Coelln R; Mandir AS; Trinkaus DB; Farah MH; Leong Lim K; Calingasan NY; Flint Beal M; Dawson VL; Dawson TM
    Neurobiol Dis; 2007 May; 26(2):312-22. PubMed ID: 17336077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.